Cargando…

A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients

Kidney transplant recipients receiving calcineurin inhibitor-based immunosuppression incur increased long-term risks of cancer and kidney fibrosis. Switch to mammalian target of rapamycin (mTOR) inhibitors may reduce these risks. Steroid or Cyclosporin Removal After Transplant using Everolimus (SOCR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chadban, Steven J, Eris, Josette Marie, Kanellis, John, Pilmore, Helen, Lee, Po Chang, Lim, Soo Kun, Woodcock, Chad, Kurstjens, Nicol, Russ, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282427/ https://www.ncbi.nlm.nih.gov/pubmed/24279685 http://dx.doi.org/10.1111/tri.12252

Ejemplares similares

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
por: Fuchs, Uwe, et al.
Publicado: (2012)

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen
por: Zaza, Gianluigi, et al.
Publicado: (2017)

Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
por: Bergh, Niklas, et al.
Publicado: (2020)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
por: De Simone, P, et al.
Publicado: (2012)

Optimizing the Safety Profile of Everolimus by Delayed Initiation in De Novo Heart Transplant Recipients: Results of the Prospective Randomized Study EVERHEART
por: Potena, Luciano, et al.
Publicado: (2018)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR)
por: Brakemeier, Susanne, et al.
Publicado: (2019)

1383. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant Recipients
por: Sun, Hsin-Yun, et al.
Publicado: (2019)

Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause
por: Lim, Wai H., et al.
Publicado: (2018)

Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
por: de Boer, Silke E., et al.
Publicado: (2022)

Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation
por: Kelsh, Shelby E., et al.
Publicado: (2018)

One-year Outcome of Everolimus With Standard-dose Tacrolimus Immunosuppression in De Novo ABO-incompatible Living Donor Kidney Transplantation: A Retrospective, Single-center, Propensity Score Matching Comparison With Mycophenolate in 42 Transplants
por: Noguchi, Hiroshi, et al.
Publicado: (2019)

Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
por: Uchida, Junji, et al.
Publicado: (2018)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Everolimus‐facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2‐year results from the subgroup analysis of the TRANSFORM study
por: Watarai, Yoshihiko, et al.
Publicado: (2021)

Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
por: Tedesco-Silva, Helio, et al.
Publicado: (2016)

Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients
por: de Boer, S. E., et al.
Publicado: (2021)

Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation
por: Chapman, William C., et al.
Publicado: (2017)

Everolimus and papillomavirus lesions in female renal transplant recipient: A case report
por: Simundic, T., et al.
Publicado: (2018)

Renal Outcomes of Liver Transplantation Recipients Receiving Standard Immunosuppression and Early Renal Sparing Immunosuppression: A Retrospective Single Center Study
por: Sharma, Pratima, et al.
Publicado: (2019)

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients
por: O'Leary, Jacqueline G., et al.
Publicado: (2016)

In Vivo Evaluation of Dual-Targeted Nanoparticles Encapsulating Paclitaxel and Everolimus
por: Houdaihed, Loujin, et al.
Publicado: (2019)

Kidney transplant recipient perspectives on telehealth during the COVID‐19 pandemic
por: Huuskes, Brooke M, et al.
Publicado: (2021)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

Pantoprazole Does not Affect Serum Trough Levels of Tacrolimus and Everolimus in Liver Transplant Recipients
por: Bremer, Sebastian C. B., et al.
Publicado: (2018)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
por: Liu, Jinyu, et al.
Publicado: (2017)

Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study
por: Klintmalm, G B, et al.
Publicado: (2014)

Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients
por: Chow, Kai Ming, et al.
Publicado: (2015)

Ganciclovir-Resistant Cytomegalovirus Infection in a Kidney Transplant Recipient Successfully Treated with Foscarnet and Everolimus
por: Menghi, Viola, et al.
Publicado: (2016)

Everolimus-associated alveolar hemorrage relapse after drug discontinuation in a kidney transplant recipient
por: Busutti, Marco, et al.
Publicado: (2022)

Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
por: Nashan, Bjorn, et al.
Publicado: (2015)

Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy
por: Pyka, Łukasz, et al.
Publicado: (2020)

Early Introduction of Everolimus Immunosuppressive Regimen in Liver Transplantation with Extra-Anatomic Aortoiliac-Hepatic Arterial Graft Anastomosis
por: Felli, Emanuele, et al.
Publicado: (2014)

Outcomes of Liver Transplant Recipients With Autoimmune Liver Disease Using Long-Term Dual Immunosuppression Regimen Without Corticosteroid
por: Satapathy, Sanjaya K., et al.
Publicado: (2017)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Determinants of Antibody Response to SARS-CoV-2 Vaccines in Liver Transplant Recipients: The Role of Immunosuppression Reduction
por: Cheng, Chih-Hsien, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q64m9p033fjf0h442gocsf25dg